Trial · NCT00829738
Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease
NCT00829738, Completed, Nycomed; results first posted 2010-09-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease. Trials, record NCT00829738. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00829738
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease
- NCT number
- NCT00829738
- Status
- Completed
- Enrollment
- 4,188 participants, actual
- Lead sponsor
- Nycomed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Pantoprazole
- First posted
- 2009-01-27
- Last updated
- 2012-05-08
- Results first posted
- 2010-09-24
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Heartburn | 14 days | Physician's assessment on a scale with 1=none, 2=mild, 3=moderate, 4=severe |
| Primary | Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Eructation/Sour Eructation | 14 days | Physician's assessment on a scale with 1=none, 2=mild, 3=moderate, 4=severe |
| Primary | Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Painful Swallowing | 14 days | Physician's assessment on a scale with 1=none, 2=mild, 3=moderate, 4=severe |
| Primary | Assessment of Pantoprazole at Final Visit: Efficacy Regarding Reflux Symptoms | 14 days | Physician's assessment on a scale with 1=excellent, 2=good, 3=satisfactory, 4=not satisfactory |
| Secondary | Functional Dyspepsia Symptoms: Assessment of the Severity of Upper Abdominal Pain | 14 days | Physician's assessment on a scale with 1=none, 2=mild, 3=moderate, 4=severe |
| Secondary | Functional Dyspepsia Symptoms: Assessment of the Severity of Sensation of Fullness | 14 days | Physician's assessment on a scale with 1=none, 2=mild, 3=moderate, 4=severe |
| Secondary | Functional Dyspepsia Symptoms: Assessment of the Severity of Nausea | 14 days | Physician's assessment on a scale with 1=none, 2=mild, 3=moderate, 4=severe |
| Secondary | Assessment of Pantoprazole at Final Visit: Efficacy Regarding Dyspeptic Symptoms | 14 days | Physician's assessment on a scale with 1=excellent, 2=good, 3=satisfactory, 4=not satisfactory |
| Secondary | Irritable Bowel Syndrome: Assessment of the Severity of Lower Abdominal Pain | 14 days | Physician's assessment on a scale with 1=none, 2=mild, 3=moderate, 4=severe |
| Secondary | Irritable Bowel Syndrome: Assessment of the Severity of Diarrhoea | 14 days | Physician's assessment on a scale with 1=none, 2=mild, 3=moderate, 4=severe |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Heartburn | 14 days | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | units on a scale | MEAN |
| PRIMARY | Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Eructation/Sour Eructation | 14 days | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | units on a scale | MEAN |
| PRIMARY | Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Painful Swallowing | 14 days | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | units on a scale | MEAN |
| PRIMARY | Assessment of Pantoprazole at Final Visit: Efficacy Regarding Reflux Symptoms | 14 days | Patients included and treated with at least one application of pantoprazole (without imputation of missing values), intention to treat | percentage of participants | NUMBER |
| SECONDARY | Functional Dyspepsia Symptoms: Assessment of the Severity of Upper Abdominal Pain | 14 days | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | units on a scale | MEAN |
| SECONDARY | Functional Dyspepsia Symptoms: Assessment of the Severity of Sensation of Fullness | 14 days | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | units on a scale | MEAN |
| SECONDARY | Functional Dyspepsia Symptoms: Assessment of the Severity of Nausea | 14 days | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | units on a scale | MEAN |
| SECONDARY | Assessment of Pantoprazole at Final Visit: Efficacy Regarding Dyspeptic Symptoms | 14 days | Patients included and treated with at least one application of pantoprazole (without imputation of missing values), intention to treat | percentage of participants | NUMBER |
| SECONDARY | Irritable Bowel Syndrome: Assessment of the Severity of Lower Abdominal Pain | 14 days | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | units on a scale | MEAN |
| SECONDARY | Irritable Bowel Syndrome: Assessment of the Severity of Diarrhoea | 14 days | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | units on a scale | MEAN |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 outcomesResults by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Heartburn | Pantoprazole | Start of therapy | 3.10 | Standard Deviation 0.80 | units on a scale |
| Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Heartburn | Pantoprazole | End of study | 1.36 | Standard Deviation 0.52 | units on a scale |
| Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Eructation/Sour Eructation | Pantoprazole | Start of therapy | 2.75 | Standard Deviation 0.89 | units on a scale |
| Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Eructation/Sour Eructation | Pantoprazole | End of study | 1.30 | Standard Deviation 0.50 | units on a scale |
| Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Painful Swallowing | Pantoprazole | Start of therapy | 1.87 | Standard Deviation 0.93 | units on a scale |
| Reflux-associated Gastrointestinal Symptoms: Assessment of the Severity of Painful Swallowing | Pantoprazole | End of study | 1.06 | Standard Deviation 0.24 | units on a scale |
| Assessment of Pantoprazole at Final Visit: Efficacy Regarding Reflux Symptoms | Pantoprazole | Excellent | 79.0 | percentage of participants | |
| Assessment of Pantoprazole at Final Visit: Efficacy Regarding Reflux Symptoms | Pantoprazole | Good | 19.2 | percentage of participants | |
| Assessment of Pantoprazole at Final Visit: Efficacy Regarding Reflux Symptoms | Pantoprazole | Satisfactory | 1.2 | percentage of participants | |
| Assessment of Pantoprazole at Final Visit: Efficacy Regarding Reflux Symptoms | Pantoprazole | Not satisfactory | 0.1 | percentage of participants |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pantoprazole | 4,188 | |
| Overall Study | COMPLETED | Pantoprazole | 4,180 | |
| Overall Study | NOT COMPLETED | Pantoprazole | 8 |
Source ClinicalTrials.gov
Adverse events7
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Pantoprazole | 1 | 4,188 | 1 |
| other | Dyspepsia | Gastrointestinal disorders | Pantoprazole | 1 | 4,188 | 1 |
| other | Nausea | Gastrointestinal disorders | Pantoprazole | 1 | 4,188 | 1 |
| other | Alanine aminotransferase increased | Investigations | Pantoprazole | 1 | 4,188 | 1 |
| other | Dizziness | Nervous system disorders | Pantoprazole | 1 | 4,188 | 1 |
| serious | Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Pantoprazole | 1 | 4,188 | 1 |
| serious | Pancreatic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Pantoprazole | 1 | 4,188 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pantoprazole | ||
| Total, other adverse events | Pantoprazole | 3 | 4,188 |
| Total, serious adverse events | Pantoprazole | 2 | 4,188 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00829738
GET https://conductscience.org/api/trials/v1/NCT00829738/results?page=2